^
    1d
    CAAA603D12101: A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=58 --> 20
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + ER positive
    |
    capecitabine • AAA603
    1d
    Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)
    P2/3, N=212, Not yet recruiting, Gruppo Oncologico Del Nord Ovest
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    1d
    mRCAT-III: Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer (clinicaltrials.gov)
    P3, N=170, Active, not recruiting, Sir Run Run Shaw Hospital | Recruiting --> Active, not recruiting | Trial completion date: Aug 2026 --> Dec 2028
    Enrollment closed • Trial completion date
    |
    MSI (Microsatellite instability) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    1d
    Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study (clinicaltrials.gov)
    P2, N=92, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    1d
    Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2028 --> Dec 2031 | Trial primary completion date: Dec 2028 --> Dec 2031
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    capecitabine
    3d
    Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, National Cancer Centre, Singapore | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • irinotecan
    3d
    Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study (clinicaltrials.gov)
    P2, N=44, Active, not recruiting, Harbin Medical University
    New P2 trial
    |
    capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    3d
    Treatment of HER2-Positive Brain Metastasis from Cervical Cancer Using Multimodal Therapy Including Pyrotinib: A Case Report. (PubMed, Int J Womens Health)
    This case illustrates successful management of HER2-positive brain metastases from cervical cancer using a multimodal approach combining surgery, radiotherapy, and systemic therapy with pyrotinib and capecitabine. The durable complete response with manageable toxicity underscores the therapeutic potential of HER2-targeted therapy as part of a multimodal regimen; however, further studies are required to validate these findings and optimize personalized treatment strategies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    |
    capecitabine • Irene (pyrotinib)
    3d
    Immunotherapy in Pediatric Constitutional Mismatch Repair Deficiency (CMMRD)-Associated Colorectal Cancer: Report of a Rare Variant and Recommendations for Screening. (PubMed, J Pediatr Hematol Oncol)
    This case highlights the use of immunotherapy and screening for pediatric CMMRD-associated colorectal adenocarcinoma in the setting of a novel PMS2 variant.
    Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
    |
    PMS2 (PMS1 protein homolog 2)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine • oxaliplatin
    4d
    Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)
    P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    6d
    Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study. (PubMed, Eur J Breast Health)
    The HER2CLIMB trial demonstrated the benefit of tucatinib, trastuzumab and capecitabine (TTC) in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC). Treatment discontinuation due to toxicity occurred in 7.4% of participants; there were no treatment-related deaths. In this national real-world cohort, TTC demonstrated clinically meaningful activity and was not associated with any new safety signals in HER2-positive ABC, including patients previously exposed to T-Dxd and those with brain metastases.
    Clinical • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Tukysa (tucatinib)
    7d
    A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov)
    P1, N=102, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440